EMA advances in implementation of transparency policy and publishes new clinical data

Eveline Van Keymeulen

On 19 December 2016, the European Medicines Agency (EMA) issued an updated version of the External guidance on the implementation of EMA Policy 0070 on publication of clinical data for human medicines. A Summary document outlines the main changes introduced by the revision.

As the EMA advances in the implementation of its transparency policy, data on two additional medicinal products (Praxbind and Tarceva) have been made available as of today on the EMA’s dedicated website, which was launched on 20 October 2016.

This post was originally co-authored by Marco de Morpurgo.

Read comments below or add a comment
Comments published on the Life Sciences Hub do not necessarily reflect the views of Allen & Overy or its clients.

Leave a comment

Your e-mail address will not be published. Required fields are marked *